TherapeuticsMD

TXMDPhase 3

Boca Raton, United StatesFounded 2008therapeuticsmd.com

TherapeuticsMD, Inc. is a public company that historically specialized in creating advanced hormone therapy solutions for women's health, particularly in contraception and menopause management. Its major achievement was securing FDA approval for two novel products: a long-acting reversible contraceptive and a bio-identical hormone therapy. After facing commercialization challenges and financial pressures, the company divested its prescription business to Mayne Pharma in 2022 and currently focuses on its over-the-counter prenatal vitamin, vitaMedMD, while exploring strategic alternatives for its remaining assets.

Market Cap

$3.3B

Founded

2008

Employees

1-50

Focus

Biotech

TXMD · Stock Price

USD 287.50+177.50 (+161.36%)

Historical price data

AI Company Overview

Technology Platform

Focused on the development and standardization of bio-identical hormone therapy (BHT) formulations and innovative drug delivery systems, such as a long-acting vaginal ring for contraception.

Pipeline Snapshot

7 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Estradiol + Placebo	Vulvovaginal Atrophy	Phase 3
Progesterone + Placebo	Secondary Amenorrhea	Phase 3
Estradiol + Progesterone + Placebo	Menopause	Phase 3
oral estradiol 1.0 mg + oral progesterone 100 mg	Menopause	Phase 3
Estradiol + placebo	Menopause	Phase 2

Funding History

Total raised: $335M

Debt$200MRoyalty PharmaJun 15, 2017

IPO$70MUndisclosedOct 11, 2012

Series B$45MUndisclosedSep 15, 2011

Series A$20MUndisclosedMay 15, 2008

Opportunities

The primary opportunity lies in successfully executing a strategic alternative, such as a reverse merger, that could repurpose the public shell for a new business.

The remaining vitaMedMD brand, though small, represents a stable, if limited, commercial asset.

Risk Factors

Existential risk is high as the company explores a sale or dissolution with no ongoing drug development.

Shareholder value is dependent on the outcome of the strategic review and the distribution of remaining cash, with potential for minimal or no return.

Competitive Landscape

Historically competed against large pharma in women's health (e.g., Pfizer, Bayer, Organon). Its differentiation was novel drug delivery (ANNOVERA) and bio-identical formulations, but it struggled with commercial execution against entrenched competitors with vast sales and marketing resources.